ClinicalTrials.gg
RecruitingNCT06835426Updated Feb 19, 2025

High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins

An interventional study of Single intravenous injection of the radiotracer and Imaging resected specimen using the high-resolution PET-CT specimen imager in Breast Carcinoma, Prostate Cancer Surgery and Thyroid Cancer, sponsored by Algemeen Ziekenhuis Maria Middelares. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Algemeen Ziekenhuis Maria Middelares · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Aug 2023, registered Dec 2024).
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 549 studies in Breast Neoplasms with a site in Belgium — 72 open to participants now, 137 under way, 64 of them phase 3. Breast Neoplasms · Belgium.

Planned enrollment
253rd of 486
150 · median 166
Started
2023
with 24 others
No phase
75 of 549
22 open now
Primary completion
2027-01
later than 67 of 136 live
Registered
524th of 549
by date

Among the 549 studies in Breast Neoplasms with a site in Belgium, this one is the 253rd largest by planned enrollment of the 486 interventional ones that give a count, is one of 25 that started in 2023, is one of 75 with no phase, reaches primary completion later than 67 of the 136 other live ones, and was the 524th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

72 of the 549 studies in Breast Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 549 studies in Breast Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease. In this process, it is important that the tumor is removed correctly and completely. To verify that the correct tissue was completely removed, the tissue is examined microscopically. However, a microscopic analysis takes a relatively long time and the result is not known until a few days after the surgery is completed. If that microscopic analysis should eventually reveal that the tumor was not completely removed, additional treatment is usually necessary. An assessment of the excised tissue during surgery would allow additional tissue to be excised in the same operation if necessary. Thus, in this way, additional treatments can also be avoided. This could lead to shorter treatment time and less emotional strain for the patient, as well as lower costs. To date, however, there are no effective techniques to do this.

PositronEmissionTomography (PET) imaging can be used to image the tumor that needs to be excised. To do this, a tracer must be administered through the blood before the operation. This tracer is a slightly radioactive substance that can be detected by the PET camera even at low concentrations. This technique is already routinely used in the hospital to detect cancer or inflammatory tissue in the body. During this study, however, it's not the intention to look at the tumor while it is still in the patient's body, but rather after it has been cut out of the patient's body by the surgeon. To do this, the piece of tissue cut away will be scanned using a specially designed PET-CT scanner.

The overall goal of this study is to gain additional knowledge. More specifically, the investigators wish to determine which medical conditions may benefit from high-resolution PET-CT specimen imaging.

Read the detailed description

The rationale of this pilot study is to obtain scientific knowledge on the clinical usefulness of perioperative high-resolution PET-CT specimen imaging in different clinical indications and to document the radiation safety of perioperative high-resolution PET-CT specimen imaging.

The study will investigate the clinical value of perioperative high-resolution PET-CT specimen imaging in breast, prostate, thyroid, head \& neck, skin, and primary and secondary hepatobiliary cancer, parathyroid adenoma, brain cancer, suspected malignant and benign gastrointestinal lesions, neuro-endocrine malignancies, genitourinary malignancies (including bladder cancer, renal pelvis and ureter carcinoma, adrenal cortical carcinoma and renal cell carcinoma), thoracovascular malignancies and in patients undergoing biopsy after metabolic active lesions were detected.

The secondary objectives of the study are:

  • to correlate the margin status based on high-resolution PET-CT specimen images with the margin status based on microscopic histopathological analysis;
  • to compare the visualization of the target lesion between perioperative high-resolution PET-CT specimen imaging and pre-operative standard-of-care imaging (e.g. whole-body PET-CT imaging, MRI imaging etc);
03

Conditions studied

  • Breast Carcinoma
  • Prostate Cancer Surgery
  • Thyroid Cancer
  • Parathyroid Adenomas
  • Skin Cancer
  • Genitourinary Cancer
  • Head and Neck Cancer
  • Hepatobiliary Cancers
  • Metabolic Abnormality
  • Neuro Endocrine Tumours
  • Brain Tumours
  • Gastro Intestinal Cancer
  • Thoracoscopic Surgery

Keywords

  • resective surgery
  • perioperative high-resolution PET-CT specimen imaging
  • breast cancer
  • Prostate cancer
  • thyroid cancer
  • parathyroid cancer
  • head and neck cancer
  • neuro-endocrine malignancies
  • genitourinary malignacies
  • thoracovascular malignancies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

A. Inclusion Criteria:

  • able to understand treatment protocol and form
  • estimated by the investigator to be compliant for study participation

    1. Fulfilling all group-specific inclusion criteria:
  • confirmed breast cancer with an indication to undergo breast conserving surgery
  • confirmed prostate cancer with an indication to undergo resective surgeryprostatectomy;
  • confirmed thyroid lesion with an indication to undergo resective surgery;
  • confirmed parathyroid adenoma with an indication to undergo resective surgery;
  • suspected basal cell carcinoma, squamous cell carcinoma or melanoma with an indication to undergo resective surgery;
  • suspected lesion in genitourinary sites (including bladder cancer, renal pelvis and ureter carcinoma, adrenal cortical carcinoma and renal cell carcinoma) with an indication to undergo resective surgery;
  • suspected lesion in the head \& neck region with an indication to undergo resective surgery;
  • confirmed primary or secondary hepatobiliary cancer with an indication to undergo resective surgery;
  • patients undergoing after metabolic active lesions were detected on a PET scan.
  • suspected neuro-endocrine with an indication to undergo resective surgery.
  • suspected brain tumor with an indication to undergo resective surgery.
  • Suspected malignant and benign gastrointestinal lesions with an indication to undergo resective surgery.
  • suspected malignant thoracovascular lesions with an indication to undergo resective surgery

B. Exclusion Criteria:

  • general or local for resective surgery;
  • in case of FDG-based PET tracers: a blood glucose level over 200 mg/dL on the day of surgery;
  • pregnancy or lactation;
  • participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Single arm

    This is a single-arm interventional pilot study. Patients eligable for this study who signed the Informed consent will be included and will follow the interventions as described.

    Other: Single intravenous injection of the radiotracer · Diagnostic Test: Imaging resected specimen using the high-resolution PET-CT specimen imager

Interventions

  • OtherSingle intravenous injection of the radiotracer

    * only in case of 18F-FDG as PET-tracer: blood glucose level is measured; * single intravenous injection of the radiotracer between 30 minutes and 5 hours (ideally between 60 and 90 minutes) before the specimen is imaged. The type and dose of radiotracer depends on the patient group: * breast cancer group: 0.8 MBq/kg of 18F-FDG * prostate cancer group: 1 MBq/kg 18F-PSMA * thyroid cancer group: 1 MBq/kg of 18F-FDG * parathyroid adenoma group: 1 MBq/kg of 18F-Choline * head \& neck cancer group: 1 MBq/kg of 18F-FDG * skin cancer group: 4 MBq/kg of 18F-FDG * primary and secondary hepatobiliary tumors group: 1 MBq/kg of 18F-FDG * genitourinary malignancies group: 1 MBq/kg of 18F-FDG * metabolic active lesions undergoing biopsy: 1 MBq/kg of 18F-FDG * Neuro-endocrine malignancies group: 1 MBq/kg of 18F-FDG * Brain tumor group: 1 MBq/kg of 18F-FDG, 18F-Choline or 18F * Gastrointestinal group: 1 MBq/kg of 18F-FDG * Thoracovascular group: 1MBq/kg of 18F-FDG

  • Diagnostic testImaging resected specimen using the high-resolution PET-CT specimen imager

    * the resected specimen is imaged in the operation theatre using the high-resolution PET-CT specimen imager (XEOS Aura; XEOS Medical, Ghent, Belgium); in principle no treatment decisions will be taken based on the images acquired by the specimen imager; however a decision to extend the resection can be taken at the discretion of the surgeon if there is clinical suspicion of a positive resection margin; * additional resected tissue (e.g. lymph nodes, cavity shaves etc) could also be imaged by the high-resolution PET-CT specimen imager; no treatment decisions will be taken based on the images acquired by the specimen imager;

06

What researchers measure

Primary outcomes

  1. Correlation of margin status

    to correlate the margin status based on high-resolution PET-CT specimen images with the margin status based on microscopic histopathological analysis

    Time frame: Up to 2 weeks after surgery (histopathology results)

Secondary outcomes

  1. Comparison of the visualization of the target lesion

    post-hoc comparison of the visualization of the target lesion between perioperative high-resolution PET-CT specimen imaging and pre-operative standard-of-care imaging (if recent pre-operative scan available). This will include lesion dimensions (e.g. delineation based on percentage of SUVmax) but also tumor to background ratio variability;

    Time frame: From pre-operative imaging until imaging during surgery

07

Study locations

1 of 1 sites recruiting
  • AZ Maria Middelares
    Gent, Oost Vlaanderen 9000, Belgium
    Recruiting
    • Steffi Ryckaert, Clinical Research Centre Manag · Contactsteffi.ryckaert@mijnziekenhuis.be · +32 9 246 18 51
    • Ine Dauwe, Clinical Research Centre · Contactklinische.studies@mijnziekenhuis.be · 003292461852
    • Bieke Lambert, MD, PhD · Contact
    • Peter Dekuyper, MD · Contact
    • Anthony Van Baelen, MD · Contact
    • Filip Ameye, MD · Contact
    • Karel Decaestecker, Prof, MD, PhD · Contact
    • Dieter Berwouts, MD · Contact
    • Sam Dekeyser, MD · Contact
    • Valérie Vergucht, MD · Contact
    • Giorgio Hallaert, MD · Contact
    • Christophe Vanclooster, MD · Contact
    • Carole Van Haverbeke, MD · Contact
    • Barbara Geeroms, MD · Contact
    • Kenneth Carels, MD, PhD · Contact
    • Annick De Craene, MD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jan 2027, 41 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 41 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Feb 19, 2025
StartActual
Aug 6, 2023
Primary completionEst.
Jan 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06835426
Lead sponsor
Algemeen Ziekenhuis Maria Middelares
Responsible party
Tessa Van Oostveldt (Principal Investigator, Algemeen Ziekenhuis Maria Middelares) — Principal investigator
First posted
Feb 19, 2025
Start date
Aug 6, 2023
Primary completion
Jan 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 19, 2025

Study contacts

Tessa Van Oostveldt
Contact
klinische.studies@mijnziekenhuis.be
+3292468000
Steffi Ryckaert
Contact
steffi.ryckaert@mijnziekenhuis.be
003292461851

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion